首页> 外文OA文献 >Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
【2h】

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

机译:HER-2 / neu转基因小鼠自发性乳腺肿瘤表现出的免疫优势大鼠HER-2 / neu MHC I类抗原决定簇的鉴定和表征。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The HER-2/neu (neu-N)-transgenic mice are a clinically relevant model of breast cancer. They are derived from the parental FVB/N mouse strain and are transgenic for the rat form of the proto-oncogene HER-2/neu (neu). In this study, we report the identification of a MHC class I peptide in the neu protein that is recognized by CD8(+) T cells derived from vaccinated FVB/N mice. This 10-mer was recognized by all tumor-specific FVB/N T cells generated regardless of the TCR Vbeta region expressed by the T cell or the method of vaccination used, establishing it as the immunodominant MHC class I epitope in neu. T cells specific for this epitope were able to cure FVB/N mice of transplanted neu-expressing tumor cells, demonstrating that this is a naturally processed peptide. Altered peptide analogs of the epitope were analyzed for immunogenicity. Vaccination with dendritic cells pulsed with a heteroclitic peptide provided FVB/N and neu-N mice with increased protection against tumor challenge as compared with mice immunized with dendritic cells loaded with either wild-type or irrelevant peptide. Discovery of this epitope allows for better characterization of the CD8(+) T cell responses in the neu-N mouse model in which neu-specific tolerance must be overcome to produce effective antitumor immunity.
机译:HER-2 / neu(neu-N)-转基因小鼠是乳腺癌的临床相关模型。它们源自亲本FVB / N小鼠品系,并且是大鼠原癌基因HER-2 / neu(neu)的转基因形式。在这项研究中,我们报告了neu蛋白中I类MHC肽的鉴定,该蛋白被来自接种FVB / N小鼠的CD8(+)T细胞识别。不论该T细胞表达的TCR Vbeta区域或所使用的疫苗接种方法如何,生成的所有肿瘤特异性FVB / N T细胞均可识别该10-mer,将其确定为neu中IHC的主要免疫表位。对该表位具有特异性的T细胞能够治愈FVB / N小鼠,所述FVB / N小鼠移植了表达neu的肿瘤细胞,这证明这是一种天然加工的肽。分析表位的改变的肽类似物的免疫原性。与用载有野生型或无关肽的树突状细胞免疫的小鼠相比,用异源肽脉冲的树突状细胞进行疫苗接种可使FVB / N和neu-N小鼠具有增强的抗肿瘤攻击能力。此表位的发现可以更好地表征neu-N小鼠模型中的CD8(+)T细胞反应,在该模型中必须克服neu特异性耐受才能产生有效的抗肿瘤免疫力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号